Vaccine Derived Poliovirus (VDPV).

Q2 Medicine Infezioni in Medicina Pub Date : 2023-01-01 DOI:10.53854/liim-3102-5

Aroop Mohanty, Ranjana Rohilla, Kamran Zaman, Vivek Hada, Surakchhya Dhakal, Abhishek Shah, Bijaya Kumar Padhi, Zahra Haleem Al-Qaim, Kauthar Jaffar A Altawfiq, Raghavendra Tirupathi, Ranjit Sah, Jaffar A Al-Tawfiq

{"title":"Vaccine Derived Poliovirus (VDPV).","authors":"Aroop Mohanty, Ranjana Rohilla, Kamran Zaman, Vivek Hada, Surakchhya Dhakal, Abhishek Shah, Bijaya Kumar Padhi, Zahra Haleem Al-Qaim, Kauthar Jaffar A Altawfiq, Raghavendra Tirupathi, Ranjit Sah, Jaffar A Al-Tawfiq","doi":"10.53854/liim-3102-5","DOIUrl":null,"url":null,"abstract":"<p><p>Poliomyelitis is caused by Poliovirus, a member of a large group of enteroviruses. Vaccine-derived polioviruses (VDPVs) stem from mutated live poliovirus, which is contained in the Oral Polio Virus vaccine (OPV). In addition, the emergence of VDPV is one of the global challenges for the eradication of poliomyelitis. VDPVs continue to affect different parts of the world; 1081 cases occurred in 2020 and 682 cases in 2021. There are several reasons that may have caused the increase in circulating vaccine-derived poliovirus (cVDPV) after the \"switch\" from the trivalent to the bivalent oral polio vaccine. One reason is the low vaccination rate among the targeted population, which has been further aggravated by the COVID-19 pandemic. Several strategies could control the spread of VDPV including the use of the monovalent OPV (mOPV-2). The risk of VDPV can be minimized through increased immunization rates and the use of safer vaccine alternatives. The global effort to eradicate polio has made significant progress over the years, but continued vigilance and investment in immunization programs are needed to achieve the ultimate goal of a polio-free world.</p>","PeriodicalId":52423,"journal":{"name":"Infezioni in Medicina","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241397/pdf/1124-9390_31_1_2023_174-185.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infezioni in Medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53854/liim-3102-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Poliomyelitis is caused by Poliovirus, a member of a large group of enteroviruses. Vaccine-derived polioviruses (VDPVs) stem from mutated live poliovirus, which is contained in the Oral Polio Virus vaccine (OPV). In addition, the emergence of VDPV is one of the global challenges for the eradication of poliomyelitis. VDPVs continue to affect different parts of the world; 1081 cases occurred in 2020 and 682 cases in 2021. There are several reasons that may have caused the increase in circulating vaccine-derived poliovirus (cVDPV) after the "switch" from the trivalent to the bivalent oral polio vaccine. One reason is the low vaccination rate among the targeted population, which has been further aggravated by the COVID-19 pandemic. Several strategies could control the spread of VDPV including the use of the monovalent OPV (mOPV-2). The risk of VDPV can be minimized through increased immunization rates and the use of safer vaccine alternatives. The global effort to eradicate polio has made significant progress over the years, but continued vigilance and investment in immunization programs are needed to achieve the ultimate goal of a polio-free world.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

疫苗衍生脊髓灰质炎病毒(VDPV)。

脊髓灰质炎是由脊髓灰质炎病毒引起的，脊髓灰质炎病毒是一大群肠道病毒中的一员。疫苗衍生脊髓灰质炎病毒(VDPVs)源于口服脊髓灰质炎病毒疫苗(OPV)中含有的突变活脊髓灰质炎病毒。此外，脊髓灰质炎的出现是根除脊髓灰质炎的全球挑战之一。vdpv继续影响世界不同地区;2020年1081例，2021年682例。在从三价口服脊髓灰质炎疫苗“切换”到二价口服脊髓灰质炎疫苗后，可能有几个原因导致循环疫苗衍生脊髓灰质炎病毒(cVDPV)增加。原因之一是目标人群的疫苗接种率较低，而COVID-19大流行进一步加剧了这一情况。几种策略可以控制VDPV的传播，包括使用单价OPV (mOPV-2)。通过提高免疫接种率和使用更安全的替代疫苗，可以最大限度地降低流行性腮腺炎和流行性腮腺炎的风险。多年来，全球根除脊髓灰质炎的努力取得了重大进展，但需要继续保持警惕并对免疫规划进行投资，以实现无脊髓灰质炎世界的最终目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Infezioni in Medicina Medicine-Infectious Diseases

CiteScore

8.40

自引率

0.00%

发文量

期刊介绍： The Journal publishes original papers, in Italian or in English, on topics concerning aetiopathogenesis, prevention, epidemiology, diagnosis, clinical features and therapy of infections, whose acceptance is subject to the referee’s assessment. The Journal is of interest not only to infectious disease specialists, microbiologists and pharmacologists, but also to internal medicine specialists, paediatricians, pneumologists, and to surgeons as well. The Editorial Board includes experts in each of the above mentioned fields.